ArticleFrontiers in aging neuroscience2023
Predictors of cognitive impairment in newly diagnosed Parkinson's disease with normal cognition at baseline: A 5-year cohort study.
Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of glucocerebrosidase gene variations on the risk of Parkinson's disease dementia: a meta-analysis.Frontiers in aging neuroscience · 2025Pooled it
- Epigenetic Aging Clocks Associate with Cognitive Status but Not Cognitive Decline: Evidence from the Parkinson's Progression Markers Initiative.medRxiv : the preprint server for health sciences · 2026Article
- Creation of a machine learning-based model for early identification of mild cognitive impairment risk in Parkinson's disease: A PD research center-based population study.Journal of Parkinson's disease · 2026Article
- RNA-seq analysis reveals altered gene expression profiles in HMEC-1 cells overexpressing KRAS gene associated with brain arteriovenous malformation.Chinese neurosurgical journal · 2026Article
- Predictive factors of global cognitive impairment in de novo Parkinson disease with normal cognition at baseline: a 10-year cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Differences and contributors to global cognitive performance in the underrepresented Latinx Parkinson's disease population.The Clinical neuropsychologist · 2025Article
- A novel method to assess motor planning deficits in patients with parkinson's disease and mild cognitive impairment.Scientific reports · 2025Article
- Multi-cohort machine learning identifies predictors of cognitive impairment in Parkinson's disease.NPJ digital medicine · 2025Article
- Comprehensive clinical scale-based machine learning model for predicting subthalamic nucleus deep brain stimulation outcomes in Parkinson's disease.Neurosurgical review · 2025Article
- Cross-modal fusion of brain imaging and clinical data for Parkinson's disease progression prediction.PloS one · 2025Article
- The role ofFrontiers in neuroscience · 2025Review
- Nomogram to predict 5-year global cognitive impairment inFrontiers in neuroscience · 2025Article
- Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome.Movement disorders clinical practice · 2024Article
- Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions.Nature communications · 2024Review
- A nomogram based on neuron-specific enolase and substantia nigra hyperechogenicity for identifying cognitive impairment in Parkinson's disease.Quantitative imaging in medicine and surgery · 2024Article
- The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis.The Lancet regional health. Europe · 2024Article
- Associations between cognitive screening performance and motor symptoms in Parkinson's disease:a systematic review and meta-analysis.Dementia & neuropsychologia · 2024Review
- Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Cognitive impairment (CI) is a substantial contributor to the disability associated with Parkinson's disease (PD). We aimed to assess the clinical features and explore the underlying biomarkers as predictors of CI in patients with newly diagnosed PD (NDPD; less than 2 years). Methods: We evaluated the cognitive function status using the Montreal Cognitive Assessment (MoCA) and a battery of neuropsychological tests at baseline and subsequent annual follow-up for 5 years from the Parkinson's Progression Markers Initiative (PPMI) database. We assessed the baseline clinical features, apolipoprotein ( Results: A total of 409 patients with NDPD with 5-year follow-up were enrolled, 232 with normal cognitive function at baseline, and 94 patients developed CI during the 5-year follow-up. In multivariate analyses, age, current diagnosis of hypertension, baseline MoCA scores, Movement disorder society Unified PD Rating Scale part III (MDS-UPDRS III) scores, and Conclusion: In NDPD, the development of CI during the 5-year follow-up can be predicted with good accuracy using a model combining age, current diagnosis of hypertension, baseline MoCA scores, MDS-UPDRS III scores, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.